Cargando...
Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?
Advances in tumor biology and cancer genetics have led to the development of effective targeted therapies in oncology over the past decade. However, targeted drug development for urothelial carcinoma has been slower than for some other malignancies. The path forward in drug development is through a...
Guardado en:
| Publicado en: | Am Soc Clin Oncol Educ Book |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6776417/ https://ncbi.nlm.nih.gov/pubmed/23714499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/EdBook_AM.2013.33.195 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|